The virtual “2.0” version of Mindleap is an online platform that supports the integration of psychedelics to support personal wellness and mental health.
According to Mydecine, the platform features a media library with guided meditations, educational content and an online community connecting users to mental health specialists.
READ: Mydecine selects substance use disorder and smoking cessation for its psychedelic molecule MYCO-004
Users can attend encrypted video support sessions through the platform and receive advice from health and wellness specialists, who work with psychedelics.
The content on Mindleap is developed in conjunction with researchers and practitioners from the field of mental health, neuroscience and psychedelics, from institutions such as Imperial College of London, Yale, and MAPS.
“The platform provides the optimal community space for users to develop trust in and connect with support professionals,” said Nicholas Martin, Mindleap’s director of specialists and community, said in a statement. “Users will be able to connect with integration specialists, who have demonstrated experience and training from psychedelic integration training programs.”
Mydecine said that Mindleap is also being designed to support patient care and monitoring for the parent company’s clinical trials.
Denver-based Mydecine’s development pipeline includes its flagship product MYCO-001, which is a purified form of psilocybin, that is being tested as a novel therapy for post-traumatic stress disorder (PTSD).
Contact Angela at email@example.com
Follow her on Twitter @AHarmantas